Royalty Pharma (RPRX) Enterprise Value (2020 - 2026)

Royalty Pharma has reported Enterprise Value for 8 years, with the latest figure at $2.4 billion in Q1 2026.

• Quarterly Enterprise Value rose 21.99% year-over-year to $2.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 21.99% YoY) and the FY2025 annual result came in at $2.6 billion, up 7.97% from the prior year.
• Enterprise Value declined to $2.4 billion in Q1 2026 per RPRX's latest filing, from $2.6 billion in the prior quarter.
• Over five years, Enterprise Value peaked at $3.1 billion in Q4 2023 and troughed at $1.4 billion in Q2 2023.
• A 5-year average of $2.3 billion and a median of $2.4 billion in 2024 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value sank 44.83% in 2022, then surged 70.46% in 2025.
• Over 5 years, Enterprise Value stood at $2.2 billion in 2022, then jumped by 41.65% to $3.1 billion in 2023, then retreated by 21.35% to $2.4 billion in 2024, then grew by 7.97% to $2.6 billion in 2025, then dropped by 6.17% to $2.4 billion in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $2.4 billion, $2.6 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.